Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Finasteride: a 5 alpha-reductase inhibitor

J F Steiner1

  • 1School of Human Medicine, University of Wyoming, Casper 82601.

Clinical Pharmacy
|January 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The corona contracts in a black-hole transient.

Nature·2019
Same author

Anomalous Hall Effect in Type-I Weyl Metals.

Physical review letters·2017
Same author

Impact on glycated haemoglobin of a biological response-based measure of medication adherence.

Diabetes, obesity & metabolism·2015
Same author

Comparative-effectiveness research in distributed health data networks.

Clinical pharmacology and therapeutics·2011
Same author

Prevalence of chronic medical conditions among jail and prison inmates in the USA compared with the general population.

Journal of epidemiology and community health·2009
Same author

Initial validation of an instrument to identify barriers to self-management for persons with co-morbidities.

Chronic illness·2006
Same journal

Criteria for use of epoetin alfa in adult cancer and orthopedic-surgery patients.

Clinical pharmacy·1993
Same journal

Accuracy of unbound-quinidine concentration determination after ultrafiltration.

Clinical pharmacy·1993
Same journal

Modified Michaelis-Menten equation for estimating unbound-phenytoin concentrations.

Clinical pharmacy·1993
Same journal

Predicting vancomycin pharmacokinetics by using aminoglycoside pharmacokinetics.

Clinical pharmacy·1993
Same journal

Efficacy of nutritional supplements used by athletes.

Clinical pharmacy·1993
Same journal

Low-molecular-weight heparins for the treatment of deep-vein thrombosis.

Clinical pharmacy·1993
See all related articles

Finasteride, an antiandrogen medication, effectively treats benign prostatic hyperplasia (BPH) by inhibiting 5 alpha-reductase. While it reduces prostate size and improves urinary symptoms, treatment success varies among patients.

Area of Science:

  • Pharmacology
  • Urology
  • Endocrinology

Background:

  • Benign prostatic hyperplasia (BPH) is an androgen-dependent condition characterized by prostate gland enlargement.
  • Dihydrotestosterone (DHT) is crucial for the hyperplastic process in BPH.
  • Finasteride belongs to the azasteroid class, exhibiting tissue-specific antiandrogenic activity.

Purpose of the Study:

  • To review the pharmacology and pharmacokinetics of finasteride.
  • To describe the clinical efficacy, adverse effects, and dosage of finasteride in BPH patients.
  • To evaluate finasteride as a pharmacologic alternative to surgery for BPH.

Main Methods:

  • Review of pharmacological and pharmacokinetic data for finasteride.
  • Analysis of clinical study results regarding finasteride's efficacy and safety in BPH.

Related Experiment Videos

  • Description of finasteride's mechanism of action as a 5 alpha-reductase inhibitor.

    • Main Results:

    • Finasteride effectively reduces prostatic volume and improves urinary flow rates.
    • Obstructive and irritative BPH symptoms are decreased with finasteride treatment.
    • Treatment success rates for BPH with finasteride range from 33% to 50% due to BPH heterogeneity.

    Conclusions:

    • Finasteride is a well-absorbed oral medication with a favorable pharmacokinetic profile.
    • Adverse effects include decreased libido and ejaculatory disorders; prostate-specific antigen levels are also affected.
    • The recommended dosage is 5 mg/day orally, with evaluation after six months of continuous therapy.